137 related articles for article (PubMed ID: 2166721)
1. Ifosfamide and mesna in combination with other cytostatic drugs in the treatment of patients with advanced cancer.
Falkson G; Chasen MR; Falkson HC
Invest New Drugs; 1990 May; 8(2):215-9. PubMed ID: 2166721
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
Glisson B; Lee JS; Palmer J; Fossella F; Shin DM; Murphy WK; Perez-Soler R; Hong WK
Cancer; 1998 Jan; 82(2):301-8. PubMed ID: 9445186
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of cisplatin, ifosfamide with mesna, and etoposide (PIE) chemotherapy for advanced non-small cell lung cancer.
Shirinian M; Lee JS; Dhingra HH; Greenberg J; Hong WK
Semin Oncol; 1992 Feb; 19(1 Suppl 1):49-53. PubMed ID: 1329212
[TBL] [Abstract][Full Text] [Related]
4. Salvage chemotherapy in refractory germ cell tumors with etoposide (VP-16) plus ifosfamide plus high-dose cisplatin. A VIhP regimen.
Ghosn M; Droz JP; Theodore C; Pico JL; Baume D; Spielmann M; Ostronoff M; Moran A; Salloum E; Kramar A
Cancer; 1988 Jul; 62(1):24-7. PubMed ID: 3133101
[TBL] [Abstract][Full Text] [Related]
5. [Preliminary result of advanced soft tissue sarcoma treated by MAID regimen].
Huang YH; Wen XP; Hu L
Ai Zheng; 2002 Aug; 21(8):907-9. PubMed ID: 12478905
[TBL] [Abstract][Full Text] [Related]
6. Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma.
Wiltshaw E; Westbury G; Harmer C; McKinna A; Fisher C
Cancer Chemother Pharmacol; 1986; 18 Suppl 2():S10-2. PubMed ID: 3102088
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of ifosfamide and etoposide chemotherapy for extensive-disease small-cell lung cancer.
Chen YM; Wu MF; Perng RP; Chou CM; Yang KY; Lin WC; Tsai CM; Liu JM; Whang-Peng J
Jpn J Clin Oncol; 1997 Apr; 27(2):76-9. PubMed ID: 9152794
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study.
Graziano SL; Valone FH; Herndon JE; Crawford J; Richards F; Rege VB; Clamon G; Green MR
Lung Cancer; 1996 Jun; 14(2-3):315-29. PubMed ID: 8794413
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin plus oral etoposide in the treatment of patients with advanced small cell lung cancer. Japan Clinical Oncology Group.
Asamoto H; Kawahara M; Iwami F; Kuba M; Furuse K; Tamura T; Saijo N; Shimoyama M
Jpn J Clin Oncol; 1998 Dec; 28(12):745-8. PubMed ID: 9879292
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of ifosfamide in combination with etoposide and cisplatin in the treatment of extensive small cell lung cancer.
Evans WK; Stewart D; Logan D; Maroun J; Goss G; Shepherd FA; Latreille J; Warner E; Dahrouge S
Semin Oncol; 1992 Dec; 19(6 Suppl 12):51-6. PubMed ID: 1336622
[TBL] [Abstract][Full Text] [Related]
11. Ifosfamide, cisplatin, and etoposide (ICE) in the treatment of advanced non-small cell lung cancer.
Shepherd FA; Evans WK; Goss PE; Latreille J; Logan D; Maroun J; Stewart D; Warner E; Paul K
Semin Oncol; 1992 Feb; 19(1 Suppl 1):54-8. PubMed ID: 1329213
[TBL] [Abstract][Full Text] [Related]
12. Experience with ifosfamide combinations (etoposide or DDP) in non-small cell lung cancer.
Drings P; Abel U; Bülzebruck H; Stiefel P; Kleckow M; Manke HG
Cancer Chemother Pharmacol; 1986; 18 Suppl 2():S34-9. PubMed ID: 3028662
[TBL] [Abstract][Full Text] [Related]
13. A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study.
Graziano SL; Herndon JE; Richards F; DiFino S; Modeas C; Duggan DB; Green MR
Cancer; 1993 Jul; 72(1):62-8. PubMed ID: 8389667
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of ifosfamide combined with Mesna uroprotection in advanced non-small-cell lung carcinoma and other solid tumors.
Nobile MT; Rosso R; Brema F; Cinquegrana A; Santi L
Tumori; 1984 Oct; 70(5):433-7. PubMed ID: 6438851
[TBL] [Abstract][Full Text] [Related]
15. Experience with ifosfamide and etoposide combination chemotherapy in extensive-disease small-cell lung cancer.
Wu MF; Perng RP; Chen YM; Liu JM; Yang SL; Whang-Peng J
Zhonghua Yi Xue Za Zhi (Taipei); 1997 Aug; 60(2):67-73. PubMed ID: 9360330
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support.
Elias AD; Ayash LJ; Wheeler C; Schwartz G; Tepler I; Gonin R; McCauley M; Mazanet R; Schnipper L; Frei E
Bone Marrow Transplant; 1995 Mar; 15(3):373-9. PubMed ID: 7599561
[TBL] [Abstract][Full Text] [Related]
17. The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16-213, doxorubicin and vincristine (VPAV) for small cell lung cancer.
Cantwell BM; Bozzino JM; Corris P; Harris AL
Eur J Cancer Clin Oncol; 1988 Feb; 24(2):123-9. PubMed ID: 2833398
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary.
Crotzer DR; Wolf JK; Gano JB; Gershenson DM; Levenback C
Gynecol Oncol; 2007 May; 105(2):399-403. PubMed ID: 17292457
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer.
Lund B; Hansen OP; Hansen HH; Hansen M
Semin Oncol; 1992 Feb; 19(1 Suppl 1):26-9. PubMed ID: 1411618
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
Wolf M; Havemann K; Holle R; Gropp C; Drings P; Hans K; Schroeder M; Heim M; Dommes M; Mende S
J Clin Oncol; 1987 Dec; 5(12):1880-9. PubMed ID: 2824710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
